Core Viewpoint - Maipu Medical plans to acquire 100% equity of Yijie Medical for 335 million yuan, aiming to enhance its capabilities in the neuro-interventional field, which is seen as a significant technological integration in the medical consumables sector [1] Financial Performance - In the first half of 2025, Maipu Medical reported revenue of 158 million yuan, a year-on-year increase of 29.28% [1] - Revenue breakdown includes: artificial dura (spinal) membrane patch at 71 million yuan (up 3.24%), craniofacial repair and fixation system at 44 million yuan (up 24.69%), and absorbable regenerated oxidized cellulose and dura adhesive totaling 38 million yuan (up 169.66%) [1] - The overall gross margin for the company was 80.59%, an increase of 1.74 percentage points year-on-year [1] Acquisition Details - The acquisition price is determined through negotiation between the parties involved, reflecting a differentiated pricing strategy [1] - Yijie Medical is expected to significantly reduce losses starting in 2026, with projected average net profit corresponding to a price-to-earnings ratio of 13.80 times from 2026 to 2029, aligning with comparable transactions [1] - Performance compensation commitments indicate projected net profits for Yijie Medical from 2025 to 2029, with a gradual transition to profitability starting in 2026 [1] Market Position and Strategy - The acquisition aligns with national policies encouraging mergers and acquisitions in the medical device sector, potentially expanding market reach and enhancing product lines [1] - Maipu Medical's core products have good market acceptance, with projected sales for 2024 reaching 156 million yuan for artificial dura (spinal) membrane patches, 79.9 million yuan for craniofacial repair systems, and 36.01 million yuan for absorbable regenerated oxidized cellulose hemostatic products [1] - The collaboration is expected to create significant synergies, benefiting from both policy and market drivers, and enhancing competitive barriers in the neuro-interventional field [1]

（编辑 李波） 从业务和交易相似性的角度，易介医疗预计自2026年起亏损大幅减少，2026年至2029年预测的平均净利 润测算，对应市盈率为13.80倍，与可比交易基本一致，标的公司估值具有合理性。 公开资料显示，迈普医学目前在神经外科领域已涵盖脑膜修复、颅颌面修补及固定、止血材料等业务。 易介医疗则在神经介入领域具备丰富的技术储备和产品布局，产品线包括神经介入导管、导丝、球囊扩 张导管等，其中Easyport远端通路导管、Speedpass血栓抽吸导管、Easytork神经血管导丝等产品已在国 内获批上市，并通过了国际质量体系认证。 通过收购易介医疗，迈普医学不仅能够拓展其在神经介入领域的市场覆盖面，还能借助易介医疗在神经 内科领域的技术积累，将神经外科与神经内科产品线有效结合，从而提升其在神经科室的整体市场竞争 力，实现产品线的横向延伸。 本报讯 （记者王镜茹）10月16日，广州迈普再生医学科技股份有限公司（以下简称"迈普医学"）发布 最新公告，公司拟通过发行股份及支付现金方式以3.35亿元收购广州易介医疗科技有限公司（以下简 称"易介医疗"）100%股权，这次被视为"神经介入领域技术整合"的收购计划，将 ...

Core Viewpoint - Maipu Medical (SZ 301033) announced the convening of its 15th meeting of the third board of directors on October 16, 2025, to review various reports related to a transaction [1] Company Summary - For the fiscal year 2024, Maipu Medical's revenue composition is as follows: 97.51% from implantable medical devices and 2.49% from other sources [1] - As of the report date, Maipu Medical has a market capitalization of 4.7 billion yuan [1]

Core Viewpoint - Maipu Medical plans to acquire 100% equity of Yijie Medical for 334.85 million yuan, marking a significant breakthrough in the "neuro-interventional field technology integration" [1] Financial Performance - In the first half of 2025, Maipu Medical achieved revenue of 158 million yuan, a year-on-year increase of 29.28%, with specific product revenues showing varied growth rates [1] - The overall gross profit margin of the company was 80.59%, an increase of 1.74 percentage points year-on-year [1] Valuation and Profitability - The acquisition pricing is based on a differentiated pricing method, considering various factors including exit strategies and investment costs [2] - Yijie Medical is expected to significantly reduce losses starting in 2026, with projected net profits from 2026 to 2029 indicating a path to profitability [2][3] Strategic Integration - The acquisition is expected to enhance Maipu Medical's capabilities in the neuro-interventional field, complementing its existing product lines in neurosurgery [4] - Maipu Medical's core products have shown good market acceptance, with significant sales figures reported for key items [4] Market Position and Policy Environment - The acquisition aligns with national policies encouraging mergers and acquisitions in the medical device industry, potentially enhancing Maipu Medical's competitiveness in high-end medical consumables [5] - The combined product offerings are expected to strengthen market presence and create competitive barriers in the neuro-interventional sector [5] Industry Trends and Synergies - The collaboration between Maipu Medical and Yijie Medical is expected to leverage policy benefits and market demand, contributing to the domestic replacement of high-value medical consumables [6] - The medical device industry in China is projected to reach a scale of 1.2 trillion yuan by 2025, with high-value consumables accounting for over 30% of the market [6]

标的公司在国内已与超过200家经销商达成合作，产品覆盖全国超过200家三甲医院，标的公司的终端客 户主要为医院的神经科室，潜在终端客户与上市公司具有较高的重合度。本次交易完成后，通过渠道资 源的协同，可以整合上市公司和标的公司全国范围内神经科室的经销商渠道和推广体系，拓宽销售区 域，更高效地开展神经科室的营销工作。上市公司对于神经科室治疗的医疗器械拥有长期研发经验和深 厚技术积累，建立了业内领先的技术平台，在生物合成材料领域积累了丰富经验。标的公司对于神经介 入手术的治疗方式和医疗器械研发需求有着深刻的认知。本次收购完成后，标的公司可助力上市公司将 生物合成材料技术由植入领域扩展至介入领域，打造介入生物材料的研发优势。 格隆汇10月16日丨迈普医学(301033.SZ)公布，公司拟通过发行股份及支付现金的方式向泽新医疗等10 名交易对方购买易介医疗100%股权，交易价格33,484.94万元。标的公司主要从事泛血管介入领域的神 经内外科医疗器械的研发、设计和销售，主要产品包括神经内外科领域的治疗类产品、通路类产品等。 本次交易完成后，上市公司将进一步拓展产品品类，形成多元化的产品矩阵。 ...

【迈普医学：拟购买易介医疗100%股权】智通财经10月16日电，迈普医学(301033.SZ)公告称，公司拟 发行股份及支付现金购买广州易介医疗科技有限公司100%股权，交易价格为3.35亿元。同时，公司计 划向广州易见医疗投资有限公司募集配套资金1.34亿元。 转自：智通财经 ...

Core Viewpoint - The company plans to acquire 100% equity of Yijie Medical for a total transaction price of 334.85 million yuan, aiming to expand its product offerings in the neuro-interventional medical device sector [1] Group 1: Acquisition Details - The acquisition will be executed through a combination of share issuance and cash payment [1] - Yijie Medical specializes in the research, design, and sales of medical devices in the neuro-interventional field, including treatment and access products [1] Group 2: Market Position and Synergies - Yijie Medical has established partnerships with over 200 distributors and its products are available in more than 200 top-tier hospitals across the country [1] - The target company's primary customers are neurology departments in hospitals, which overlap significantly with the company's existing customer base [1] - Post-acquisition, the company aims to leverage the combined distribution channels and marketing systems to enhance sales efficiency in neurology departments [1] Group 3: Technological and R&D Advantages - The company possesses extensive R&D experience and a strong technical foundation in medical devices for neurology [1] - The acquisition will enable the company to extend its expertise in biocomposite materials from the implantation field to the interventional field, enhancing its R&D capabilities in interventional biomaterials [1]

迈普医学公告，公司拟发行股份及支付现金购买广州易介医疗科技有限公司100%股权，交易价格为 3.35亿元。同时，公司计划向广州易见医疗投资有限公司募集配套资金1.34亿元，发行股票数量为 232.91万股，发行价格为57.35元/股。 ...

股东会通知 证券代码：301033 证券简称：迈普医学 公告编号：2025-076 广州迈普再生医学科技股份有限公司 关于召开 2025 年第三次临时股东会的通知 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 广州迈普再生医学科技股份有限公司（以下简称"公司"）于 2025 年 10 月 16 日召开第三届董事会第十五次会议，审议通过了《关 于召开 2025 年第三次临时股东会的议案》，会议决定于 2025 年 11 月 3 日召开公司 2025 年第三次临时股东会，现将有关事项通知如下： 一、召开会议的基本情况 1、股东会届次：2025 年第三次临时股东会 2、股东会的召集人：董事会 （2）网络投票时间：通过深圳证券交易所系统进行网络投票的 股东会通知 具体时间为 2025 年 11 月 3 日 9:15-9:25，9:30-11:30，13:00-15:00； 通过深圳证券交易所互联网投票系统投票的具体时间为2025年11月 3 日 9:15 至 15:00 的任意时间。 5、会议的召开方式：现场表决与网络投票相结合。 6、会议的股权登记日：2025 年 ...

广州迈普再生医学科技股份有限公司董事会 关于本次交易中是否存在直接或间接有偿聘请 其他第三方机构或个人的说明 广州迈普再生医学科技股份有限公司（以下简称"上市公司"、 "公司"）拟通过发行股份及支付现金的方式购买广州泽新医疗科技 有限公司、广州易创享投资合伙企业（有限合伙）等 10 名交易对方 合计持有的广州易介医疗科技有限公司100%股权并募集配套资金（以 下简称"本次交易"）。 为保证本次交易顺利实施，公司聘请了以下第三方机构： （一）聘请华泰联合证券有限责任公司作为本次交易的独立财务 顾问； （二）聘请北京市中伦律师事务所作为本次交易的法律顾问； （四）聘请广东联信资产评估土地房地产估价有限公司作为本次 交易的资产评估机构。 （五）聘请深圳市谦同企业咨询有限公司作为本次交易募投项目 的可行性研究咨询机构。 经核查，上述聘请行为合法合规，除上述聘请行为外，上市公司 本次交易不存在直接或间接有偿聘请其他第三方的行为。 特此说明。 广州迈普再生医学科技股份有限公司 董事会 2025 年 10 月 16 日 （三）聘请华兴会计师事务所（特殊普通合伙）作为本次交易的 审计机构及审阅机构； ...